Ester Fernández‐Salas

3.2k total citations · 1 hit paper
37 papers, 2.1k citations indexed

About

Ester Fernández‐Salas is a scholar working on Molecular Biology, Oncology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Ester Fernández‐Salas has authored 37 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 11 papers in Oncology and 5 papers in Cellular and Molecular Neuroscience. Recurrent topics in Ester Fernández‐Salas's work include Protein Degradation and Inhibitors (9 papers), Ubiquitin and proteasome pathways (8 papers) and Botulinum Toxin and Related Neurological Disorders (5 papers). Ester Fernández‐Salas is often cited by papers focused on Protein Degradation and Inhibitors (9 papers), Ubiquitin and proteasome pathways (8 papers) and Botulinum Toxin and Related Neurological Disorders (5 papers). Ester Fernández‐Salas collaborates with scholars based in United States, Ireland and China. Ester Fernández‐Salas's co-authors include Shaomeng Wang, Stuart H. Yuspa, Christina Cheng, Chao‐Yie Yang, Wendy C. Weinberg, K. Roger Aoki, Jeanne A. Stuckey, Krishnapriya Chinnaswamy, Xin Han and Joanne Wang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Ester Fernández‐Salas

34 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer

2019 303 citations Ester Fernández‐Salas, Mi Wang et al. profile →

Peers

Countries citing papers authored by Ester Fernández‐Salas

Since Specialization

Citations

This map shows the geographic impact of Ester Fernández‐Salas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ester Fernández‐Salas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ester Fernández‐Salas more than expected).

Fields of papers citing papers by Ester Fernández‐Salas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ester Fernández‐Salas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ester Fernández‐Salas. The network helps show where Ester Fernández‐Salas may publish in the future.

Co-authorship network of co-authors of Ester Fernández‐Salas

This figure shows the co-authorship network connecting the top 25 collaborators of Ester Fernández‐Salas. A scholar is included among the top collaborators of Ester Fernández‐Salas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ester Fernández‐Salas. Ester Fernández‐Salas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Harnessing CD39 inhibition to boost antitumor immunity with extracellular ATP 2025 ·The Journal of Immunology ·Ke Jin, (unknown), (unknown), Jenna L. Pappalardo, (unknown), Soonweng Cho, Nigel P.C. Walker, Matthew J. Walters, Ester Fernández‐Salas, (unknown)	0
2	Abstract 2478: Inhibition of CD39 by AB598 increases extracellular ATP resulting in activation of myeloid cells and T cells to enhance anti-tumor immunity 2024 ·Cancer Research ·Ke Jin, (unknown), (unknown), (unknown), (unknown), (unknown), Matthew J. Walters, Ester Fernández‐Salas, (unknown)	1
3	880 Inhibition of AXL signaling with AB801 augments anti-tumor immune responses 2023 ·SHILAP Revista de lepidopterología ·Jhansi L. Leslie, (unknown), Eugene Park, (unknown), (unknown), Samantha C. Schwager, (unknown), (unknown), (unknown), Ester Fernández‐Salas, (unknown)	1
4	Abstract 518: AB801 is a highly potent and selective AXL kinase inhibitor that demonstrates significant anti-tumor activity 2023 ·Cancer Research ·(unknown), (unknown), (unknown), (unknown), (unknown), Jhansi L. Leslie, Dillon H. Miles, (unknown), (unknown), Manjunath Lamani, (unknown), (unknown), (unknown), Ada Chen, (unknown), (unknown), (unknown), (unknown), (unknown), Ester Fernández‐Salas	1
5	Abstract B08: AB598, a therapeutic anti-CD39 antibody, elevates ATP and increases immunogenicity in the tumor microenvironment 2022 ·Cancer Immunology Research ·(unknown), (unknown), (unknown), (unknown), (unknown), Ke Jin, (unknown), (unknown), (unknown), Stephen W. Young, Nigel P.C. Walker, Matthew J. Walters, Ester Fernández‐Salas, (unknown)	1
6	Design of the First‐in‐Class, Highly Potent Irreversible Inhibitor Targeting the Menin‐MLL Protein–Protein Interaction 2017 ·Angewandte Chemie International Edition ·Shilin Xu, Angelo Aguilar, Tianfeng Xu, Ke Zheng, Liyue Huang, Jeanne A. Stuckey, Krishnapriya Chinnaswamy, Denzil Bernard, Ester Fernández‐Salas, Liu Liu, Mi Wang, Donna McEachern, Sally Przybranowski, (unknown), Shaomeng Wang	51
7	A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation 2017 ·Nature Communications ·Haibin Zhou, Jianfeng Lü, Liu Liu, Denzil Bernard, (unknown), Ester Fernández‐Salas, Krishnapriya Chinnaswamy, (unknown), Jeanne A. Stuckey, Qing Yu, Weihua Zhou, Zhen‐Qiang Pan, Yi Sun, Shaomeng Wang	77
8	Design of the First‐in‐Class, Highly Potent Irreversible Inhibitor Targeting the Menin‐MLL Protein–Protein Interaction 2017 ·Angewandte Chemie ·Shilin Xu, Angelo Aguilar, Tianfeng Xu, Ke Zheng, Liyue Huang, Jeanne A. Stuckey, Krishnapriya Chinnaswamy, Denzil Bernard, Ester Fernández‐Salas, Liu Liu, Mi Wang, Donna McEachern, Sally Przybranowski, (unknown), Shaomeng Wang	2
9	Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non–Small Cell Lung Cancer Cells 2016 ·Neoplasia ·(unknown), Ester Fernández‐Salas, Enxiao Li, Shaomeng Wang	56
10	Role of BET proteins in castration-resistant prostate cancer 2016 ·Drug Discovery Today Technologies ·Ester Fernández‐Salas, Shaomeng Wang, Arul M. Chinnaiyan	14
11	Septin Dynamics Are Essential for Exocytosis 2015 ·Journal of Biological Chemistry ·Elmíra Tokhtaeva, (unknown), Elizabeth A. Marcus, Julian P. Whitelegge, (unknown), É. A. Bukharaeva, (unknown), Laura A. Dada, George Sachs, Ester Fernández‐Salas, Olga Vagin	65
12	Identification of Fibroblast Growth Factor Receptor 3 (FGFR3) as a Protein Receptor for Botulinum Neurotoxin Serotype A (BoNT/A) 2013 ·PLoS Pathogens ·(unknown), (unknown), Jérôme Dupuy, Jeremy B. Nelson, (unknown), (unknown), Joanne Wang, Lance E. Steward, Ron S. Broide, Joseph Francis, K. Roger Aoki, Raymond C. Stevens, Ester Fernández‐Salas	67
13	CLIC4 is a tumor suppressor for cutaneous squamous cell cancer 2012 ·Carcinogenesis ·Kwang S. Suh, (unknown), Anjali Shukla, Andrew Ryscavage, (unknown), Kasey Jividen, John Crutchley, Rebecca A. Dumont, Ester Fernández‐Salas, Joshua D. Webster, Richard J. Simpson, Stuart H. Yuspa	40
14	Novel Chimeras of Botulinum Neurotoxins A and E Unveil Contributions from the Binding, Translocation, and Protease Domains to Their Functional Characteristics 2008 ·Journal of Biological Chemistry ·Jiafu Wang, Jianghui Meng, Gary W. Lawrence, Tomas H. Zurawski, Astrid Sasse, (unknown), M. Gilmore, Ester Fernández‐Salas, Joseph Francis, Lance E. Steward, K. Roger Aoki, J. Oliver Dolly	98
15	The Organellular Chloride Channel Protein CLIC4/mtCLIC Translocates to the Nucleus in Response to Cellular Stress and Accelerates Apoptosis 2004 ·Journal of Biological Chemistry ·Kwang S. Suh, Michihiro Mutoh, Kunio Nagashima, Ester Fernández‐Salas, Lindsay E. Edwards, Daniel Hayes, John Crutchley, (unknown), Rebecca A. Dumont, Joshua M. Levy, Christina Cheng, Susan H. Garfield, Stuart H. Yuspa	124
16	Ribonucleases expressed by human pancreatic adenocarcinoma cell lines 2000 ·European Journal of Biochemistry ·Ester Fernández‐Salas, Rosa Peracaula, Marsha L. Frazier, Rafael de Llorens	20
17	p53 and Tumor Necrosis Factor α Regulate the Expression of a Mitochondrial Chloride Channel Protein 1999 ·Journal of Biological Chemistry ·Ester Fernández‐Salas, Manish Sagar, Christina Cheng, Stuart H. Yuspa, Wendy C. Weinberg	122
18	Cloning and Characterization of a Human Genotoxic and Endoplasmic Reticulum Stress-inducible cDNA That Encodes Translation Initiation Factor 1(eIF1A121/SUI1) 1999 ·Journal of Biological Chemistry ·M. Saeed Sheikh, Ester Fernández‐Salas, (unknown), Arif Hussain, Jonathan D. Dinman, Stuart W. Peltz, Ying Huang, Albert J. Fornace	26
19	The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract 1999 ·Oncogene ·M. Saeed Sheikh, Ying Huang, Ester Fernández‐Salas, Wafik S. El‐Deiry, Helmut Friess, Sally A. Amundson, Jing Yin, Stephen J. Meltzer, Nikki J. Holbrook, Albert J. Fornace	117
20	Potato Carboxypeptidase Inhibitor, a T-knot Protein, Is an Epidermal Growth Factor Antagonist That Inhibits Tumor Cell Growth 1998 ·Journal of Biological Chemistry ·Carmen Blanco‐Aparicio, Miguel Ángel Molina‐Vila, Ester Fernández‐Salas, Marsha L. Frazier, José Manuel Mas, (unknown), Francesc Avilés, Rafael de Llorens	75

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact